LY-2584702

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameLY-2584702
Drug Alias NameLYS-6K1-tosylateLY-2584702LY-S6K1
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Action70-kDa ribosomal protein S6 kinases inhibitors
Targets70-kDa ribosomal protein S6 kinases
Therapy Area/IndicationsNeoplasm MetastasisCarcinoma, Non-Small-Cell LungCarcinoma, Renal Cell +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSingaporeFrance +[4] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEli Lilly And Company
Active IndicationsN/A
Inactive IndicationsNeoplasm MetastasisCarcinoma, Non-Small-Cell LungCarcinoma, Renal Cell +[5] 

Other Information

ATC CodeN/A
Related LinksN/A